SCHEMBL4592008

SCHEMBL4592008

C=CCOc1ccc(COCCn2ccnn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38
ATP4A P20648 1/20 0.38
ATP4B P51164 1/20 0.38
HPGD P15428 1/20 0.38
CYP19A1 P11511 3/20 0.35
ERBB2 P04626 2/20 0.35
MINK1 Q8N4C8 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
BCHE P06276 2/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049275 0.82 GAA (0.37) ALDH1A1SMN1; SMN2MAPTATP4AATP4B
SCHEMBL5050508 0.82 DPP4 (0.39) SMN1; SMN2MAPTATP4AATP4BCA12
SCHEMBL5042887 0.79 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2USP2POLBMAPT
SCHEMBL4599530 0.79 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2USP2POLBMAPT
SCHEMBL4592205 0.78 CYP19A1 (0.44) ATP4AATP4BCYP19A1
SCHEMBL4592972 0.77 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2USP2POLBMAPT
SCHEMBL5044837 0.77 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2USP2POLBMAPT
SCHEMBL5558170 0.77 CYP19A1 (0.39) ALDH1A1SMN1; SMN2MAPTATP4AATP4B
SCHEMBL5564001 0.72 IDO1 (0.44) SMN1; SMN2POLBMAPTCYP19A1NPC1
SCHEMBL27678886 0.71 CA12 (0.34) ALDH1A1SMN1; SMN2USP2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432291-B2 Ether derivatives HOFFMAN-LA ROCHE INC. (US) 2008-10-07 US disclosed
US-7429605-B2 Phenylpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-30 US disclosed
US-7405231-B2 Anticancer agents; inhibitors of the HER-signaling pathway with decreased toxicity, better solubility and improved pharmacokinetic profile; e.g. 1-[4-(4-(2-[(E)-2-(4-Methanesulfinyl-phenyl)-vinyl]-oxazol-4-ylmethoxy)-phenyl)-butyl]-1H-[1,2,3]triazole HOFFMANN-LA ROCHE INC. (US) 2008-07-29 US disclosed
CN-101213186-A Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-07-02 CN disclosed
EP-1912969-A1 PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-23 EP disclosed
US-7342030-B2 Indole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-03-11 US disclosed
CN-101010319-A Indole derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-08-01 CN disclosed
EP-1727815-B1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2007-06-27 EP disclosed
US-7235574-B2 Pentafluorosulfanyl compounds HOFFMANN-LA ROCHE INC. (US) 2007-06-26 US disclosed
EP-1797086-A1 INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2007-06-20 EP disclosed
EP-1725549-A1 PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
EP-1725551-A1 OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
WO-2006032509-A1 INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-30 WO disclosed
US-20060063812-A1 Indole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 US disclosed
WO-2005095388-A1 PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
WO-2005095393-A1 OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
WO-2005090338-A1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-09-29 WO disclosed
US-20050209290-A1 Novel ether derivatives F. HOFFMAN-LA ROCHE AG (CH) 2005-09-22 US disclosed
US-20050203064-A1 Novel oxidized thioether derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 US disclosed
US-20050197370-A1 Novel pentafluorosulfanyl compounds HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197370-A1 Novel pentafluorosulfanyl compounds SF3B5, SF3B1, SF3B3 ALDH1A1 171/4885SMN1; SMN2 1222/4885USP2 3389/4885
US-20050203064-A1 Novel oxidized thioether derivatives SULT1E1, CYP4F3, GPX4 ALDH1A1 89/4885SMN1; SMN2 2000/4885USP2 3632/4885
US-20060063812-A1 Indole derivatives IDO1, IDO2, TPH1 ALDH1A1 123/4885SMN1; SMN2 3127/4885USP2 4314/4885
US-20050209290-A1 Novel ether derivatives CYP2E1, CYP11B1, CYP11B2 ALDH1A1 244/4885SMN1; SMN2 1916/4885USP2 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.